Clinical Trials Directory

Trials / Completed

CompletedNCT03648476

Intervention to Change Attributions That Are Negative (ICAN)

Intervention to Change Attributions That Are Negative (ICAN): a New Approach to Reducing Anger and Aggression After Brain Injury

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
28 (actual)
Sponsor
Indiana University · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

ICAN is the first treatment to target hostile attributions after TBI, making it a novel anger/ aggression management approach in this population. This is a randomized waitlist control trial. The length of time in the trial is approximately 15 weeks and the intervention is 6 weeks long.

Detailed description

ICAN is the first treatment to target hostile attributions after TBI, making it a novel anger/ aggression management approach in this population. Since the investigator's prior research shows that stronger hostile attributions are associated with poorer perspective taking,39 ICAN employs a unique perspective-positioning technique to train perspective taking and reduce hostile attributions. After recalling a personal situation in which others' ambiguous actions led to an unpleasant outcome, participants will explore different perspectives: sitting or standing in one position, s/he will explore his or her own thoughts and feelings (self-perspective), then move to a different position to experience the other person's perspective, eliciting their thoughts and feelings. In 40 participants with TBI, we will conduct a Phase I, randomized waitlist controlled trial with 4 data collection points: Baseline; Week 1; Week 8 (post-treatment for ICAN; post-wait period for WLC); Week 15 (WLC post-treatment).

Conditions

Interventions

TypeNameDescription
BEHAVIORALICANA 6-week group therapy sessions once a week for 90-120 minutes.

Timeline

Start date
2018-11-02
Primary completion
2020-11-23
Completion
2021-01-11
First posted
2018-08-27
Last updated
2022-05-23
Results posted
2022-05-23

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT03648476. Inclusion in this directory is not an endorsement.